Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 743 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary; Hypertension Clear all
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 11, 2026, 7:38 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 11, 2026, 7:38 AM EDT
Not listed No phase listed Observational

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

NCT01467791
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Hypertension
Interventions
Observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 11, 2026, 7:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Phase 3 Interventional

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077
View directory record Official record
Conditions
Hypertension, Asthma
Interventions
PPCM Asthma, 24 Month PPCM BP, 9 Month PPCM BP
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
San Diego, California • Hartford, Connecticut • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 11, 2026, 7:38 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT00678821
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Aerobic exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 82 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Completed No phase listed Observational

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT00011648
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 11, 2026, 7:38 AM EDT
Completed No phase listed Observational

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

NCT00452283
View directory record Official record
Conditions
Glaucoma, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 11, 2026, 7:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

World Trade Center Adolescent Health Study

NCT02068183
View directory record Official record
Conditions
Asthma, Hypertension, Cardiovascular Risk Factor, Insulin Resistance, Stress Disorders, Post-Traumatic, Exposure to Toxic Dust
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 20 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 11, 2026, 7:38 AM EDT
Completed No phase listed Observational

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

NCT06907693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT Pulmonary Angiography Scan
Diagnostic Test
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Withdrawn Not applicable Interventional

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT02958358
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Robert Scott Harris, M.D.
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 11, 2026, 7:38 AM EDT
Withdrawn Phase 1 Interventional

A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

NCT02684786
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
reserpine, stellate ganglion block, lidocaine
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Phase 3 Interventional

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 11, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 11, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension in Left Heart Disease

NCT05935605
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Vascular Disease, Left Heart Disease
Interventions
Transthoracic Echocardiography (TTE), Lung ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Terminated Phase 3 Interventional Results available

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 11, 2026, 7:38 AM EDT
Not listed No phase listed Observational

Non-invasive Pulmonary Artery Prediction (ADOPTS)

NCT05641675
View directory record Official record
Conditions
Heart Failure, Pulmonary Arterial Hypertension
Interventions
right heart catheterization
Diagnostic Test
Lead sponsor
Silverleaf Medical Sciences INC
Industry
Eligibility
20 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 11, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

NCT03800901
View directory record Official record
Conditions
Diabetes, Hypertension, Depression, Osteoarthritis, Asthma, Pain, Heart Failure
Interventions
Continuing Medical Education, Quality IQ Patient Simulations
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 11, 2026, 7:38 AM EDT
Recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
46
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 11, 2026, 7:38 AM EDT
Not listed Not applicable Interventional

Evaluating Infrasonic Hemodynography

NCT04636892
View directory record Official record
Conditions
Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, Systolic, Cardiovascular Diseases, Coronary Artery Disease
Interventions
MindMics earbud
Other
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 11, 2026, 7:38 AM EDT
Completed No phase listed Observational

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

NCT01729611
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
17 Years to 90 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 11, 2026, 7:38 AM EDT